Drugs / EphB4-HSA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02799485 | Feb 2018 → Feb 2025 | Kaposi's sarcoma | AIDS Malignancy Consortium | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EphB4-HSA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02799485 ↗ |
| Action | Inhibit | “may block the growth of blood vessels that provide blood to the cancer” NCT02799485 ↗ |
| Modality | Protein / enzyme biologic | “recombinant EphB4-HSA fusion protein” NCT02799485 ↗ |
| Route | Intravenous | “Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 1 hour” NCT02799485 ↗ |